Uy Ear
Stock Analyst at Mizuho
(1.18)
# 1732
Out of 5,235 analysts
66
Total ratings
34.62%
Success rate
10.38%
Average return
Main Sectors:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Arcutis Biotherapeut... | Maintains: Outperform | 19 20 | 15.73 | 27.15% | 13 | Jan 7, 2025 | |
uniQure | Maintains: Neutral | 7 20 | 17.61 | 13.57% | 4 | Dec 19, 2024 | |
Relmada Therapeutics | Downgrades: Neutral | 23 1 | 0.48 | 108.33% | 1 | Dec 5, 2024 | |
Alkermes | Maintains: Outperform | 35 40 | 28.51 | 40.3% | 5 | Nov 13, 2024 | |
Sage Therapeutics | Maintains: Neutral | 18 16 | 5.97 | 168.01% | 2 | Jul 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 40 | 17.06 | 134.47% | 1 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 145 179 | 124.56 | 43.71% | 5 | May 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 25 21 | n/a | n/a | 10 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 20 23 | 10.71 | 114.75% | 3 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 116 140 | n/a | n/a | 10 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 60 24 | n/a | n/a | 4 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 35 16 | n/a | n/a | 1 | Nov 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 4 3 | n/a | n/a | 2 | Aug 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 36 40 | n/a | n/a | 1 | Jun 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Neutral | 2 | n/a | n/a | 1 | Mar 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Buy | 10 | 2.7 | 270.37% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 5 3 | 0.87 | 244.83% | 2 | Mar 1, 2023 |